Oncoinvent will participate at the ESGO 2023 congress

Oncoinvent be represented by CMO, Dr. Kari Myren at the 2023 ESGO congress.

There will also be a mini oral presentation on the theme “First Experience With Intra-Abdominal 224Radium-Labelled Microparticles (Radspherin) After Cytoreductive Surgery For Peritoneal Metastasis In Recurrent Epithelial Ovarian Cancer (Phase 1 Study)” by Dr. Els Van Nieuwenhuysen, University Hospital Leuven, Leuven, Belgium

Organiser: ESGO - European Congress of Gynaecological Oncology
Venue:

The congress venue is situated at the Istanbul Congress Center (ICC), Türkiye


Date: 29 September 2023
Program: Program

Anders Månsson

Chief Executive Officer

mansson@oncoinvent.com

+47 488 68 863

Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.

Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.